Atricure, Inc. ( (ATRC) ) has released its Q3 earnings. Here is a breakdown of the information Atricure, Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
AtriCure, Inc., a prominent player in the medical device sector, specializes in innovative surgical treatments for atrial fibrillation and related conditions, with a focus on post-operative pain management. In its latest earnings report, AtriCure announced a significant 15.8% increase in worldwide revenue for the third quarter of 2025, reaching $134.3 million. The company also reported a net loss of $0.3 million, showing a substantial improvement of $7.6 million compared to the previous year, alongside an adjusted EBITDA increase of $9.9 million. Key drivers of this growth include the successful adoption of products like the AtriClip platform and cryoSPHERE devices, as well as the EnCompass clamp. The U.S. market saw a 14.5% revenue increase, while international revenue surged by 22.0%, reflecting strong global demand. Looking ahead, AtriCure has raised its financial outlook for 2025, projecting full-year revenue between $532 million and $534 million, with adjusted EBITDA expected to range from $55 million to $57 million. The company remains focused on product innovation and expanding its market presence, aiming for continued growth and profitability.